Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pancreatic cancer
Biotech
FibroGen lays off 75% of US staff as asset flunks 2 more trials
FibroGen is stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials.
Nick Paul Taylor
Jul 31, 2024 7:22am
ASCO: Early Purple Biotech data shows gains in pancreatic cancer
Jun 1, 2024 8:00am
Clinical-stage cancer biotech Actuate latest to eye summer IPO
May 28, 2024 9:45am
AACR: Cancer vaccines get a reintroduction
Apr 10, 2024 4:30am
AACR: BioNTech cancer vax spurs immune response 3 years in
Apr 7, 2024 2:00pm
Survival mushrooms in Golden Biotech’s pancreatic cancer trial
Jan 18, 2024 9:47am
